Distribution of procyanidins and their metabolites in rat plasma and tissues in relation to ingestion of procyanidin-enriched or procyanidin-rich cocoa creams
- 857 Downloads
Procyanidins are extensively metabolized via phase-II and microbial enzymes. However, their distribution in the body is not well characterized.
This study investigates the distribution of procyanidins (monomers and dimers) and their phase-II metabolites in plasma and tissues (thymus, heart, liver, testicle, lung, kidney, spleen and brain).
Wistar rats were fed with 1 g of cocoa cream (CC), 50 mg of procyanidin hazelnut skin extract (PE) and 50 mg PE in 1 g CC (PECC). The rats were killed at 0, 1, 1.5, 2, 3, 4 and 18 h after gavage, and the plasma and tissues were analyzed by UPLC–MS/MS.
Epicatechin–glucuronide was the main metabolite in the plasma after the CC intake, with C max at 423 nM and t max at 2 h, and methyl catechin–glucuronide (301 nM, 2 h) was the main metabolite in the plasma after the PE intake. As a result of the PECC enrichment, epicatechin–glucuronide (452 nM, 1.5 h) and catechin–glucuronide (297 nM, 2 h) were the main metabolites in the plasma. Methyl catechin–glucuronide was found in the liver after PE (8 nmol/g tissue, 4 h) and PECC (8 nmol/g, 1.5 h). The kidney was found to contain a high concentration of phase-II metabolites of procyanidins and is therefore thought to be the main site of metabolism of the compounds. Methyl catechin–sulfate (6.4 nmol/g, 4 h) was only quantified in the brain and after PE intake. Catechin metabolites were not found in the spleen or heart. Phenolic acids were detected in all tissues.
The formulation of a product enriched or fortified with procyanidins is a way to increase their bioavailability, with clear effects on the plasmatic pharmacokinetics, and a greater accumulation of phenolic metabolites in such tissues as the liver, kidney, lung and brain.
KeywordsFood matrix effect Procyanidins Plasma Tissue distribution
The present study was supported by the CENIT program from the Spanish Minister of Industry and by a consortium of companies led by La Morella Nuts S.A.U. (Reus, Catalonia, Spain) with the following: Shirota Functional Foods, S.L., KRAFT; BTSA, Biotecnologias Aplicadas, S.L., Selección Batallé, S.A., Industrial Técnica Pecuaria S.A., Neuron Bio Pharma, S.A., Grupo Leche Pascual, S.A.U., Innaves, S.A. This study was also supported by the Catalan Government (Interdepartmental Commission for Research and Technological Innovation) through the A. Serra grant. The authors thank Carme Piñol (in charge) from the Animal Facility Service of the University of Lleida for their technical support.
Conflict of interest
Authors have declared no conflict of interest.
- 1.Allen L, de Bonist B, Dary O, Hurrell R (2006) Guidelines on food fortification with micronutrients. WHO Press, SwitzerlandGoogle Scholar
- 4.Faridi Z, Njike VY, Dutta S, Ali A, Katz DL (2008) Acute dark chocolate and cocoa ingestion and endothelial function: a randomized controlled crossover trial. Am J Clin Nutr 88:58–63Google Scholar
- 8.Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G, Blumberg JB, Ferri C (2008) Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 138:1671–1676Google Scholar
- 10.Shoji T, Masumoto S, Moriichi N, Akiyama H, Kanda T, Ohtake Y, Goda Y (2006) Apple procyanidin oligomers absorption in rats after oral administration: analysis of procyanidins in plasma using the porter method and high-performance liquid chromatography/tandem mass spectrometry. J Agric Food Chem 54:884–892CrossRefGoogle Scholar
- 11.Okushio K, Suzuki M, Matsumoto N, Nanjo F, Hara Y (1999) Identification of (−)-epicatechin metabolites and their metabolic fate in the rat. Drug Metab Dispos 27:309–316Google Scholar
- 18.Holt RR, Lazarus SA, Cameron Sullards M, Zhu QY, Schramm DD, Hammerstone JF, Fraga CG, Schmitz HH, Keen CL (2002) Procyanidin dimer B2 [epicatechin-(4β-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am J Clin Nutr 76:798–804Google Scholar